OVERVIEW

The Impact of phosphoinositide 3-kinase (PI3K) Inhibitors for the Treatment of Patients with Breast Cancer is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 09, 2020
Expiration Date: January 09, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This continuing medical education (CME) activity is designed to inform healthcare providers who care for patients with breast cancer of the opportunities and challenges in the management of patients with breast cancer using phosphoinositide 3-kinase (PI3K) inhibitors. The in-depth program will cover best practices for identification of patients with breast cancer who are most likely to benefit from these agents, the specific mechanistic characteristics of available agents, and techniques for managing adverse events appropriately. In addition, available clinical trial data will be examined and contextualized in patient cases, including trials of emerging strategies utilizing combination approaches incorporating PI3K inhibition.

Benefits of Participating:
• Learn the best approaches for identification of trials of PI3K inhibitors that may be appropriate for selected patients with breast cancer
• Outline clinical trials in progress and the latest developments on PI3K inhibitors in breast cancer
• Recognize the toxicity profile of PI3K inhibitors and latest strategies to diagnose and mitigate adverse events

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Explain the rationale for the use of PI3K inhibitors to treat patients with breast cancer.
• Outline the most important results from clinical trials exploring the use of PI3K inhibitors alone or in combination with other therapies for the treatment of patients with breast cancer.
• Implement strategies to identify and monitor adverse events associated with PI3K inhibitors to improve the outcome of patients with breast cancer.